PAVmed's EsoGuard® Validated as Essential Tool for Esophageal Cancer Screening

### Breakthrough Study Validates EsoGuard® as a Key Tool for Esophageal Cancer Screening

Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., announces the findings of the largest real-world study on the detection of Barrett's esophagus (BE), a precancerous condition that can lead to esophageal cancer. The study, titled "Non-Endoscopic Screening for Barrett's Esophagus Using a DNA Methylation-Based Assay: 18-Month Real-World Experience in 11,991 Patients," evaluates the effectiveness of the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. Conducted across a diverse patient population, the research positions these tools as pivotal in the early detection of esophageal cancer, a significant advancement for cancer prevention diagnostics.

The study reports an impressive 95% technical success rate for the EsoCheck procedure, which is quick, typically taking less than two minutes, and is associated with no serious adverse events. This efficiency is critical in clinical settings, where time and patient safety are paramount. The analysis also reveals that the majority of participants met the screening guidelines established by U.S. gastroenterology societies, reflecting a growing acceptance and integration of these innovative diagnostic tools into standard care practices. This alignment underscores the potential for widespread application of EsoGuard and EsoCheck in routine screenings, particularly among patients at high risk for Barrett's esophagus.

Lucid's leadership underscores the significance of these findings. Dr. Lishan Aklog, Chairman and CEO of Lucid, emphasizes that the study confirms EsoGuard's role as a fundamental component of a scalable early detection program for esophageal cancer. Furthermore, Dr. Victoria T. Lee, Chief Medical Officer, highlights the successful implementation of EsoCheck by trained personnel in various clinical settings, reinforcing its reliability and adaptability. This study not only validates the clinical effectiveness of these diagnostic tools but also signifies a promising step forward in the fight against esophageal cancer through early intervention and prevention strategies.

In accompanying news, Lucid Diagnostics continues to focus on expanding its clinical applications and enhancing patient access to early cancer detection technologies. The company remains committed to research and development efforts that improve diagnostic accuracy and patient outcomes. As this study undergoes peer review, the medical community anticipates further insights into the role of DNA methylation-based assays in cancer screening.

Overall, the release of these findings marks a significant milestone for Lucid Diagnostics and a hopeful advancement for patients at risk of esophageal cancer, highlighting the importance of innovative, non-invasive screening solutions in the landscape of cancer prevention.